Valuation: Adocia SA

Market Cap 52.36M 59.33M 49.54M 44.93M 84.23M 5.69B 85.06M 594M 229M 2.91B 223M 218M 9.36B P/E 2026 *
-3.26x
P/E 2027 * 3.87x
Enterprise Value 56.76M 64.32M 53.7M 48.7M 91.31M 6.17B 92.21M 644M 248M 3.15B 242M 236M 10.14B EV / Sales 2026 *
-
EV / Sales 2027 * 1.84x
Free-Float
96.05%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 2023-05-10
Director of Finance/CFO - 2024-09-22
Chief Tech/Sci/R&D Officer - 2014-11-30
Director TitleAgeSince
Director/Board Member 55 2013-04-18
Chairman 57 -
Director/Board Member 61 2023-05-10
Change 5-day change 1-year change 3-year change Capi.($)
+20.41%-.--% - - 58.46M
-0.70%-4.35%+56.10%+86.42% 71.81B
+0.45%-2.26%+38.36%+87.74% 60.06B
+0.19%+0.94%+36.97%+21.32% 27.93B
-1.73%-4.30%-18.37%+357.94% 25.7B
-0.51%-2.28%+0.48%-9.27% 24.89B
+0.65%+2.52%+25.89%-6.99% 20.92B
+3.46%+3.91%+158.90%+337.81% 15.04B
+0.48%+0.86%+44.56%+168.42% 14.46B
+3.91%-4.56%-2.71%+506.41% 13.87B
Average +2.66%-0.92%+37.80%+172.20% 30.52B
Weighted average by Cap. +0.19%-1.74%+38.02%+129.00%

Financials

2026 *2027 *
Net sales - 44.87M 50.84M 42.45M 38.5M 72.18M 4.88B 72.89M 509M 196M 2.49B 191M 187M 8.02B
Net income -16M -18.13M -15.14M -13.73M -25.74M -1.74B -25.99M -182M -69.99M -888M -68.08M -66.6M -2.86B -44.33M -50.23M -41.94M -38.04M -71.31M -4.82B -72.01M -503M -194M -2.46B -189M -185M -7.92B
Net Debt 4.4M 4.99M 4.16M 3.78M 7.08M 478M 7.15M 49.94M 19.25M 244M 18.72M 18.31M 786M 30.18M 34.19M 28.55M 25.89M 48.54M 3.28B 49.02M 343M 132M 1.68B 128M 126M 5.39B
Logo Adocia SA
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
73
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.628EUR
Average target price
9.700EUR
Spread / Average Target
+269.10%

Quarterly revenue - Rate of surprise